Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non–Small-Cell Lung Cancer. (11th August 2021)
- Record Type:
- Journal Article
- Title:
- Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non–Small-Cell Lung Cancer. (11th August 2021)
- Main Title:
- Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non–Small-Cell Lung Cancer
- Authors:
- Miyazawa, Tomoyuki
Otsubo, Kanji
Sakai, Hiroki
Kimura, Hiroyuki
Chosokabe, Motohiro
Morikawa, Kei
Furuya, Naoki
Marushima, Hideki
Kojima, Koji
Mineshita, Masamichi
Koike, Junki
Saji, Hisashi - Abstract:
- Background: This study aimed to determine the relationship of programmed death-ligand 1 (PD-L1) expression and standardized uptake values in fluorodeoxyglucose–positron emission tomography/computed tomography (FDG-PET/CT) with prognosis in non–small-cell lung cancer (NSCLC). Methods: We retrospectively analyzed 328 NSCLC patients who underwent lobectomy/segmentectomy with lymph node dissection. PD-L1 expression was detected by immunohistochemically stained using the murine monoclonal antibody clone 22C3. The preoperative maximum standardized uptake value (SUVmax ) of FDG-PET/CT at the primary lesion; pathological factors including histological type, microscopic lymphatic, venous, and pleural invasion; and lymph node metastases in resected specimens was determined. Significant prognostic clinicopathologic factors were analyzed by univariate and multivariate analyses. Results: PD-L1 expression was higher in men, smokers, squamous cell carcinoma, advanced pathologic stages, positive venous invasion, positive pleural invasion, and high preoperative SUVmax (≥3). Postoperative survival analysis showed that both PD-L1 expression and preoperative SUVmax were significantly negative prognostic factors in univariate analysis for overall survival (OS) ( P = 0.0123 and P < 0.0001) and relapse-free survival (RFS) ( P = 0.0012 and P < 0.0001). Kaplan–Meier survival curves showed that the OS and RFS were the best in patients with negative PD-L1 expression and SUVmax < 3, intermediate inBackground: This study aimed to determine the relationship of programmed death-ligand 1 (PD-L1) expression and standardized uptake values in fluorodeoxyglucose–positron emission tomography/computed tomography (FDG-PET/CT) with prognosis in non–small-cell lung cancer (NSCLC). Methods: We retrospectively analyzed 328 NSCLC patients who underwent lobectomy/segmentectomy with lymph node dissection. PD-L1 expression was detected by immunohistochemically stained using the murine monoclonal antibody clone 22C3. The preoperative maximum standardized uptake value (SUVmax ) of FDG-PET/CT at the primary lesion; pathological factors including histological type, microscopic lymphatic, venous, and pleural invasion; and lymph node metastases in resected specimens was determined. Significant prognostic clinicopathologic factors were analyzed by univariate and multivariate analyses. Results: PD-L1 expression was higher in men, smokers, squamous cell carcinoma, advanced pathologic stages, positive venous invasion, positive pleural invasion, and high preoperative SUVmax (≥3). Postoperative survival analysis showed that both PD-L1 expression and preoperative SUVmax were significantly negative prognostic factors in univariate analysis for overall survival (OS) ( P = 0.0123 and P < 0.0001) and relapse-free survival (RFS) ( P = 0.0012 and P < 0.0001). Kaplan–Meier survival curves showed that the OS and RFS were the best in patients with negative PD-L1 expression and SUVmax < 3, intermediate in patients with positive PD-L1 expression and SUVmax < 3 and those with negative PD-L1 expression and SUVmax ≥ 3, and poor in patients with positive PD-L1 expression and SUVmax ≥ 3. Conclusion: Combining PD-L1 expression and preoperative FDG-PET/CT SUVmax in primary tumor might help in accurate prediction of postoperative prognosis in NSCLC patients. … (more)
- Is Part Of:
- Cancer control. Volume 28(2021)
- Journal:
- Cancer control
- Issue:
- Volume 28(2021)
- Issue Display:
- Volume 28, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 28
- Issue:
- 2021
- Issue Sort Value:
- 2021-0028-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-08-11
- Subjects:
- non–small-cell lung cancer -- PD-L1 -- FDG-PET/CT
Cancer -- Prevention -- Periodicals
Cancer -- Diagnosis -- Periodicals
Cancer -- Treatment -- Periodicals
Cancer -- Palliative treatment -- Periodicals
Cancer -- Prevention
Medical Oncology
Neoplasms -- prevention & control
Neoplasms -- therapy
Electronic journals
Periodicals
Periodicals
616.994005 - Journal URLs:
- http://journals.sagepub.com/toc/ccxa/current ↗
http://bibpurl.oclc.org/web/6982 ↗
http://www.moffitt.usf.edu/pubs/ccj/ ↗
http://www.medscape.com/viewpublication/100_index ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/10732748211038314 ↗
- Languages:
- English
- ISSNs:
- 1073-2748
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20621.xml